125I粒子支架联合局部灌注化疗治疗晚期食管癌的疗效分析

目的评价125I 粒子支架植入联合局部灌注化疗治疗晚期食管癌患者的临床疗效。方法选取 2013 年1月至 2016年1月郑州大学第一附属医院收治的经病理确诊的晚期食管癌患者46例。在数字剪影血管造影机下，经口植入125I粒子覆膜食管支架。术后5～7 d行局部灌注化疗。生存质量采用卡氏评分评估，吞咽困难采用Stooler分级评定，客观疗效评价参考世界卫生组织（WHO）实体肿瘤评价标准进行影像学评价。 结果术后2个月卡氏评分较术前提高；吞咽困难Stooler分级：与术前相比，术后1周、术后1个月Stooler分级较术前降低，且术后1个月较术后1周降低，差异有统计学意义（均P＜005）。客观疗效：完全缓解11例，部分缓解23例，稳定7例，进展5例，有效率739％，获益率891％；术后1年生存率717％。结论125I 粒子食管粒子支架联合局部灌注化疗可改善晚期食管癌生活质量，是晚期食管癌有效的微创治疗方法。

To evaluate the efficacy of 125I particle stent combined with transcatheter artery chemotherapy (TAC) for patients with advanced or unresectable esophageal cancer.

Abstract: Objective: To evaluate the efficacy of 125I particle stent combined with transcatheter artery chemotherapy (TAC) for patients with advanced or unresectable esophageal cancer. Methods: a total of 46 cases were collected in our hospital from January 2013 to January 2016, all cases were confirmed by pathology. Under digital subtraction angiography (DSA), 125I particle coated esophageal stents were implanted. Transcatheter artery chemotherapy(TAC) was done 5 to 7 days after stent implantation. Chemotherapy regimens were 5-fluorouracil + cisplatin + doxorubicin or epirubicin. SPSS 19. 0 software was used to analyze the patients' KPS score, stooler swallowing grading, tumor treatment efficiency and 1 year survival rate. Results: The KPS score was significantly improved, the function of swallowing was significantly improved, and the tumor control rate was considerable. 1-year survival rate was 71.7%. Conclusion: the clinical symptoms and quality of life of advanced esophageal cancer can be significantly improved by the combination of 125I seeds stents combined with TAC. In conclusion, it is an effective minimally invasive treatment for advanced esophageal cancer.